The third phase (escape phase) begins when cancer cells become capable of binding and activating the co-inhibitory molecules on the T lymphocytes (CTLA-4, PD-1, LAG-3, TIM-3), and secreting soluble immunosuppressive or inducing the secretion of mediators such as IDO, TGFβ, IL10. The gene discussed is HAVCR2; the disease is cancer.